Search

Displaying results 2241 - 2250 of 2959 in total
  1. Drug

    Daprodustat

    go.drugbank.com/drugs/DB11682
    ApprovedInvestigational

    [L43857] On February 1, 2023, daprodustat was fully approved by the FDA as the first oral treatment for anemia caused by chronic kidney disease in patients on dialysis. … [A254157] On October 2022, the FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) supported that the benefit of treatment with daprodustat outweighs the risks for adult dialysis patients with

  2. Drug

    TRGFT-201

    go.drugbank.com/drugs/DB23064
    ApprovedInvestigational

    [L64070,L64071] It is the first regulatory T cell (Treg)-based immunotherapy approved by the FDA.[L64071] … [L64070,L64071] Orca-T was approved by the FDA on June 30, 2026 for use in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologic

  3. Drug

    N,N,N-trimethylglycinium

    go.drugbank.com/drugs/DB04455
    Investigational

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p1341)

  4. Drug

    Rubella virus vaccine

    go.drugbank.com/drugs/DB10317
    ApprovedInvestigational

    It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).

    Synonyms: Rubivirus rubella virus Wistar RA 27/3 whole, Rubella virus strain Wistar RA 27/3 live antigen
  5. Drug

    Magnesium cation

    go.drugbank.com/drugs/DB01378
    ApprovedInvestigationalNutraceuticalWithdrawn

    Magnesium hydroxide is used primarily in "Milk of Magnesia", a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. Milk of magnesia is primarily used to alleviate constipation, but can also be used...

    Mixtures: KALSİMAG-D3 1000 MG/300 MG/880 IU EFERVESAN GRANÜL, 30 ADET, KALSİMAG-D3 1000 MG/300 MG/880 IU EFERVESAN GRANÜL, 40 ADET
  6. Drug

    Resmetirom

    go.drugbank.com/drugs/DB12914
    ApprovedInvestigational

    On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD

  7. Drug

    Chlormadinone acetate

    go.drugbank.com/drugs/DB15903
    ApprovedWithdrawn

    In 1972, the FDA withdrew its approval for the use of chlormadinone acetate in all products.

    Mixtures: LUTORAL-E
  8. Drug

    Lonapegsomatropin

    go.drugbank.com/drugs/DB16220
    ApprovedInvestigational

    [L36380,L10971] Lonapegsomatropin was granted FDA approval on 25 August 2021.[L36380] It was later approved by the European Commission on 13 January 2022.[L39900]

  9. Drug

    Zongertinib

    go.drugbank.com/drugs/DB18762
    ApprovedInvestigational

    [L53873,A274363] On August 8, 2025, the US FDA granted accelerated approval to zongertinib for the treatment of advanced forms of non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain

  10. Drug

    Depemokimab

    go.drugbank.com/drugs/DB18846
    ApprovedInvestigational

    [A275338] Approved by the FDA on December 16, 2025, depemokimab is indicated as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and paediatric patients